0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

Medical News & Perspectives | 
Rita Rubin, MA
JAMA. 2015;313(23):2309-2310. doi:10.1001/jama.2015.3911.

News From the Food and Drug Administration | 
Rita Rubin, MA
JAMA. 2015;313(17):1704. doi:10.1001/jama.2015.4112.

News From the Centers for Disease Control and Prevention | 
JAMA. 2015;313(9):886. doi:10.1001/jama.2015.0700.

Viewpoint | 
Rebecca L. Haffajee, JD, MPH; Anupam B. Jena, MD, PhD; Scott G. Weiner, MD, MPH
JAMA. 2015;313(9):891-892. doi:10.1001/jama.2014.18514.
Includes: Supplemental Content

News From the Centers for Disease Control and Prevention | 
JAMA. 2015;313(8):787. doi:10.1001/jama.2015.384.

Viewpoint | 
John A. Rogers, PhD, SM
JAMA. 2015;313(6):561-562. doi:10.1001/jama.2014.17915.

Viewpoint | 
Andrew A. Monte, MD; Richard D. Zane, MD; Kennon J. Heard, MD, PhD
JAMA. 2015;313(3):241-242. doi:10.1001/jama.2014.17057.

Health Agencies Update | 
Tracy Hampton, PhD
JAMA. 2014;312(24):2608. doi:10.1001/jama.2014.17033.

News From the Centers for Disease Control and Prevention | 
JAMA. 2014;312(23):2482. doi:10.1001/jama.2014.16135.

News From the Centers for Disease Control and Prevention | 
JAMA. 2014;312(15):1504. doi:10.1001/jama.2014.12463.

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts
From The JAMA Network
JAMA Oncology
Brief Report  | 
Nephrotoxicity of the BRAF Inhibitors Vemurafenib and Dabrafenib
Kenar D. Jhaveri, MD; Vipulbhai Sakhiya, MBBS; Steven Fishbane, MD
JAMA Oncology
Invited Commentary  | 
JAK/STAT Pathway Inhibitors and Neurologic Toxicity: Above All Else Do No Harm?
Bart L. Scott, MD; Pamela S. Becker, MD, PhD
JAMA Oncology
Original Investigation  | 
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial
Animesh Pardanani, MD; Claire Harrison, MD; Jorge E. Cortes, MD; et al.
JAMA Dermatology
Original Investigation  | 
Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-analysis
Steven M. Belknap, MD; Imran Aslam, BS; Tina Kiguradze, BS; et al.